13 results about "Withaferin A" patented technology

The present application relates to the technical field of medicine, in particular to a withaferin A compound, a preparation method and application thereof.The withaferin A compound in the present application, withagulide F, is a new compound extracted, separated and purified from Physalis angulata L. for the first time, and has the development potential as a drug for treating liver fibrosis.At present, no relevant research literature discloses and reports the withaferin A compound withagulide F, and the research content of applying the withagulide F to the preparation of a drug for treating liver fibrosis.The new application of the withagulide F provided in the present application in the preparation of a drug for treating liver fibrosis has important significance for the difficult problem of liver fibrosis treatment.

The invention discloses a target-adjustable nano-pesticide, a preparation method and application, the target-adjustable nano-pesticide is prepared by creatively combining rugocitrinolide with a double-stranded RNA (Ribonucleic Acid) small groove in a groove mode to form a rugocitrinolide-double-stranded RNA compound based on an RNAi (Ribonucleic Acid Interference) technology, and wrapping the rugocitrinolide-double-stranded RNA compound with a chitosan shell. The nano-pesticide can significantly improve the stability of dsRNA so as to improve the RNA interference efficiency; moreover, the pesticide has good wettability and biocompatibility, is green and environment-friendly, and can be used as a substitute for a traditional pesticide; the dsRNA sequence can be designed in a targeted manner according to the actual occurrence condition of field diseases, targeted prevention and control of different pathogenic bacteria are realized by utilizing the difference and specificity of the sequence, and the application potential is huge.

Disclosed is a method for treating a condition, which includes the steps of: selecting a patient for treatment who has the condition; administering to the patient at least one active pharmaceutical ingredient (API); and administering to the patient at least one metal complex represented by formula (I):including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof. Also disclosed is a composition for conducting the method, which includes: at least one API selected from the group consisting of Cisplatin, Temozolomide, Vandetanib, Withaferin A, Vemurafenib, Amiodarone, Vinblastine, Metformin, Gemcitabine and Acyclovir; and at least one metal complex effective to potentiate an efficacy of the API to treat the condition, wherein the at least one metal complex is represented by formula (I), including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof.

An eyedrop for inhibiting ocular pathological angiogenesis and a preparation method therefor. The eyedrop comprises the following components in weight-volume percentage: withaferin A, a solubilizer, a thickener, an antimicrobial agent, a tonicity adjuster, and a pH-adjusting agent, with the balance being water for injection. The specific preparation method comprises: mixing withaferin A with a solubilizer, and thoroughly stirring same until a uniform mixed solution is obtained for later use; heating a thickener, a pH-adjusting agent, a tonicity adjuster and an antimicrobial agent in a water bath at 60°C under stirring until a clear and transparent solution is obtained, and then cooling the solution to room temperature; adding the mixed solution to the solution, and making same up to the volume with water for injection; and sterilizing the prepared eyedrop by means of filtration through a 0.22 μm microporous filter membrane, and performing aseptic packaging to obtain the final product. The eyedrop has a good solubility and a prolonged retention time on the ocular surface, thus having a good therapeutic effect on pathological angiogenesis in the eye, particularly on the ocular surface. Moreover, the eyedrop has the advantages of a topical ocular formulation, including a good biocompatibility, a moderate viscosity and no irritation to the eyes; and also including a good permeability, ease of use and low systemic side effects.

The present invention discloses a method for preparing the natural product 5,6-Deoxywithaferin A, belonging to the technical field of preparing natural active ingredients from plants. Using the commercially available natural product withaferin A as a raw material, the present invention achieves efficient semi-synthetic conversion of the natural product 5,6-Deoxywithaferin A through only three reaction steps. Compared with existing technologies, the synthetic route is greatly simplified and the yield is significantly improved.

The present invention provides a nadifloxacin cream, its preparation method and application. The active ingredients include the following raw materials in parts by weight: 40 - 60 parts of nadifloxacin raw material medicine, 25 - 43 parts of oily matrix, 15 - 35 parts of emulsifier, 5 - 10 parts of compound penetration enhancer, 5 - 12 parts of humectant, 3 - 6 parts of preservative, and 12 - 25 parts of purified water. The compound penetration enhancer is composed of baicalein, turmeric, enzyme inhibitor peptide, and withaferin A in a specific ratio. During the preparation process, a cream base is formed through steps such as heating, mixing, and emulsifying, then the active ingredients and preservatives are added, and high-voltage pulsed electric field and ozone intermittent treatment are used to improve the penetration performance of the cream. The cream can be used to treat skin infection diseases caused by various bacteria. The present invention provides a new strategy for the development of highly efficient and safe skin medications, is expected to improve the therapeutic effect of nadifloxacin cream, and provides strong support for the clinical treatment of skin infection diseases.

This application relates to the technical field of osteoarthritis, specifically to a preparation method of a withaferin A double-carrier complex and its application in anti-osteoarthritis. By co-loading and encapsulating withaferin A using F127 hydrogel and PEG-PCL nanomicelles to form a nanocomplex, it can improve the solubility and bioavailability of withaferin A, enabling it to more effectively target the inflammatory sites in bone tissue. This double-carrier complex has significant effects in inhibiting bone destruction and promoting bone regeneration, and may play a role by reducing inflammatory cell infiltration in the bone marrow and decreasing the release of inflammatory mediators.

The present invention relates to a medicinal composition derived from Withania somnifera extract comprising withanolides and sominone wherein said sominone in the extract is standardized in the range of 0.1-30%. Withanolides in the said composition are in the range of 10-60%. It is further comprising withanolide glycosides and withaferin A. Medicinal composition along with pharmaceutically acceptable excipients are formulated into a dosage form. It also discloses a method of preparation of said medicinal composition. Said composition is used to improve memory and cognition when administered to subjects in the appropriate dosage. Said composition is capable of enhancing the bioavailability of its constituents.

This invention discloses the use of solanine A derivatives in the preparation of drugs for the prevention or treatment of obesity, belonging to the field of pharmaceutical technology. The applicant's experimental results show that although the weight-loss activity of these solanine A derivatives is reduced compared to solanine A, they still maintain a significant weight-loss effect and can be used as candidate drugs for treating obesity and weight loss. The solanine A derivatives described in this invention are compounds having the structures shown in Formula 2, 10, or 12: [list of compounds].

This disclosure relates, in general, to withaferin A analogue compounds, compositions, and methods for treating various diseases and conditions by using a therapeutically effective amount of a compound of formula (I), a pharmaceutically acceptable salt, or a derivative thereof.

The invention provides a lipidosome for treating neuroinflammation as well as a preparation method and application thereof. The lipidosome comprises a carrier formed by assembling phospholipid, cholesterol and an amphiphilic polymer coupled with R peptide, and a medicine loaded on a hydrophobic layer of the carrier, the amino acid sequence of the R peptide comprises ERRPRGRRRGRKC; the medicine comprises any one or a combination of at least two of quercetin, curcumin, rutin, tripterine and drunkenin A. The invention further discloses a preparation method of the medicine. The surface of the carrier is subjected to R peptide functional modification, so that the interaction with epithelial cells of a nasal cavity can be enhanced, and the delivery efficiency of intranasal administration is improved; the endocytosis pathway is regulated and controlled to realize efficient internalization of the medicine, and the medicine is directly delivered to the central nervous system by bypassing the blood brain barrier through olfaction and trigeminal nerve pathways, so that the treatment of neuroinflammation is realized.

The present invention discloses a contact lens care solution for inhibiting corneal hypoxia and corneal neovascularization. The solution contains the following ingredients: withaferin A, disodium edetate, a solubilizing agent, a thickener, an antibacterial agent, an isotonicity regulator, and an appropriate amount of a pH regulator, with the remainder being water for injection. The solution specifically comprises the following steps: first, weighing withaferin A and a solubilizing agent, mixing them, and stirring them thoroughly for later use; second, weighing the above-mentioned weight-to-volume ratio of disodium edetate, a thickener, a pH regulator, an isotonicity regulator, and an antibacterial agent, heating and stirring the mixture in a 60°C water bath until clear and translucent, and then cooling to room temperature; third, adding the mixture from the first step to the solution from the second step, and adjusting the volume with water for injection to obtain a contact lens care solution; and fourth, filtering the obtained care solution through a 0.22 μm microporous membrane for sterilization and aseptically packaging. The solution has good solubility, improves corneal tissue hypoxia and corneal neovascularization caused by contact lens wear, and provides preventive and health benefits.